A recent meta-analysis showed an improved survival benefit, especially for patients aged < 70 years, with de novo AML, with positive expression of CD33, with NPM1 mutation, without FLT3-ITD mutation, and with low-/intermediate-risk karyotypes [33]. This evidence concerns the gene FLT3 and acute myeloid leukemia.